Drug Trial Radar · NCT07662395
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
May 9, 2026
Primary completion
Jan 24, 2030
Study completion Jan 24, 2030
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCLC). The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion. The Phase III portion is a randomized, double-blind, active-controlled study enrolling approximately 350 patients. Eligible participants will be randomized in a 1:1 ratio to receive SCTB41 plus chemotherapy or tislelizumab plus chemotherapy. The primary objective is to compare progression-free survival assessed by blinded independent central review according to RECIST version 1.1.
Conditions
- Double Blind
Interventions
SCTB41Drug
IV infusion,Specified dose on specified days.
TislelizumabDrug
IV infusion,Specified dose on specified days.
PaclitaxelDrug
175 mg/m², IV infusion, Q3W, for 4 cycles.
Nab-paclitaxelDrug
100 mg/m², IV infusion, on Days 1, 8, 15 of each 3-week cycle, for 4 cycles
CarboplatinDrug
AUC 5, IV infusion, Q3W, for 4 cycles.
CisplatinDrug
75 mg/m², IV infusion, Q3W, for 4 cycles.
PemetrexedDrug
500 mg/m², IV infusion, Q3W, for 4 cycles .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.